Alopecia areata

Hair and Scalp Diseases: Medical, Surgical, and Cosmetic Treatments

Volumn , Issue , 2008, Pages 91-105

  Hordinsky, Maria K ^a   Caramori, Ana Paula Avancini ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Santa Casa Complexo Hospitalar   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56649118072     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Hordinsky M, Ericson E. Autoimmunity: alopecia areata. J Invest Dermatol 2004; 9:73-38.
2. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992; 128:702.
3. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42:549-566.
4. Orecchia G, Doubille H, Marelli MA. Nail changes and alopecia areata. Ital Gen Rev Dermatol 1988; 25:179-184.
5. Elieff D, Sundby S, Kennedy W, Hordinsky M. Decreased sweat-gland number and function in patients with alopecia areata. Br J Dermatol 1991; 125:130-135.
6. de Berker D, Rees JL. Normal sweat secretion rate in patients with alopecia areata. Br J Dermatol 1995; 132:402-404.
7. Muller SA, Winkelmann RK. Alopecia areata. Arch Dermatol 1963; 88:290-297.
8. Carter DM, Jegasothy BV. Alopecia areata and Down syndrome. Arch Dermatol 1976; 112:1397-1399.
9. Van Daele, C. Down's anomaly [21 trisomy] and Turner's syndrome [46 Xxqi] in the same sib ship. Helv Paediatr Acta 1982; 25:412-420.
10. Colon EA, et al. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 1991; 32:245-251.
11. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70:628-633.
12. Ikeda T. A new classification of alopecia areata. Dermatologica 1968; 131:421-445.
13. Walker SA, Rothman S. Alopecia areata: a statistical study and consideration of endocrine influences. J Invest Dermatol 1950; 14: 403-413.
14. Nanda A, Al-Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. Pediatr Dermatol 1999; 16:6-11.
15. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996; 35:22-27.
16. Sharma VK, Kumar B, Dawn G. A clinical study of childhood alopecia areata in Chandigarh, India. Pediatr Dermatol 1996; 13:372-377.
17. Xiao FL, Yang S, Lui JB, et al. The epidemiology of childhood alopecia areata in China: a study of 226 patients. Pediatr Dermatol 2006; 23:13-18.
18. Tan E, Tay YK, Goh CL, Giam C. The pattern and profile of alopecia areata in Singapore - a study of 219 patients. Int J Dermatol 2002; 41:748-753.
19. Ro BI. Alopecia areata in Korea (1982-1994). J Dermatol 1995; 22:858-864.
20. Gilhar A, Ullmann Y, Berkutzki T, et al. Alopecia areata transferred to human scalp explants on SCID mice with T-lymphyocyte injections. J Clin Invest 1998; 101:62-67.
21. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003; 139: 1555-1559.
22. Ito T, Ito N, Betterman A, et al. Collapse and restoration of MHC class-1-dependent immune privilege; exploiting the human hair follicle as a model. Am J Pathol 2004; 164:623-634.
23. Martinez-Mir A, Zlotogorski A, Gordon D, et al. Genome-wide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007; 80:316-328.
24. Paus R, Peters EMJ, Eichmuller S, Botchkarev VA. Neural mechanisms of hair growth control. J Invest Dermatol 1997; 2:61-68.
25. Peters EMJ, Ericson M, Hosi J, et al. Neuropeptide control mechanisms in cutaneous biopsy: physiological mechanisms and clinical significance. J Invest Dermatol 2006; 126:1937-1947.
26. Willemsen R, Vanderlinden J, Deconinck A, Roseuw D. Hypnotherapeutic management of alopecia areata. J Am Acad Dermatol 2006; 55:233-237.
27. Epstein E. Evidence-based treatment of alopecia areata. J Am Acad Dermatol 2001; 45:640-641.
28. Olsen E, Hordinsky M, McDonald-Hull S, et al. Alopecia areata investigational guidelines. J Am Acad Dermatol 1999; 40:242-246.
29. Olsen EA, Hordinsky M, Price VH, et al. Alopecia areata investigational guidelines - Part II. J Am Acad Dermatol 2004; 51:440-447.
30. Sackett DL. Evidence based medicine. What it is and what it isn't. BMJ 1996; 312:71-72.
31. Freyschmidt-Paul P, Happle R, McElwee KJ, Hoffmann R. Alopecia areata: treatment of today and tomorrow. J Investig Dermatol Symp Proc 2003; 8:12-17.
32. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2002; 138:112-113.
33. Hoffmann R, Happle R. Topical immunotherapy in alopecia areata: what; how; and why? Dermatol Clin 1996; 14:739-744.
34. Olson E. Topical and systemic corticosteroids in alopecia areata. Aust Dermatol 1997; 38:20 (abstract).
35. Tosti A, Piracinni BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003; 49:96-98.
36. Fiedler VC. Alopecia areata. A review of therapy, efficacy, safety, and mechanism. Arch Dermatol 1992; 128:1519-1929.
37. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970; 141:193-202.
38. Montes LF. Topical halcinonide in alopecia areata and in alopecia totalis. J Cutan Pathol 1977; 4:47-50.
39. Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973; 88:55-59.
40. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128:1467-1473.
41. Seiter S, Ugurel S, Tilgen W, Reinhold U. High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology 2001; 202:230-204.
42. Friedli A, Labarth MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998; 39:597-602.
43. Kiesch N, Stene JJ, Goens J, Vanhooteghem O, Song M. Pulse steroid therapy for children's severe alopecia areata. Dermatology 1997; 194:395-397.
44. Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987; 16:745-748.
45. Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatolg 1987; 123:1488-1490.
46. Schmoeckel C, Weissman, I, Plewig G, Braun-Falco O. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979; 115:1254-1255.
47. Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years' experience at St. John's Institute of Dermatology. Br J Dermatol 1995; 133:914-918.
48. Stern R, Nichols K, Vakeva L. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336:1041-1045.
49. Krook G. Treatment of alopecia areata with Kromayer's ultraviolet lamp. Acta Derm Venereol 1961; 41:178-181.
50. Jury CS, McHenry P, Burden AD, et al. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol 2006; 31:196-199.
51. Bissonnette R, Shapiro J, Zeng H, McLean DI, Lui H. Topical photodynamic therapy with 5-aminolaevulinic acid does not induce hair growth in patients with extensive alopecia areata. Br J Dermatol 2000; 143:1032-1035.
52. Zakaria W, Passeron T, Ostovari N, Lacour J-P. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol 2004; 51:837-838.
53. Strober BE, Siu K, Alexis AF, Washenik K, Sinha A, Shupack JL. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005; 52:1082-1084.
54. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2006; 140:1012.
55. Bartels G, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006; 142:1653-1654.
56. Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol 2006; 55:632-636.
57. Ferry JJ, Fiedler VC. Pilot study to evaluate the effect of topical betamethasone dipropionate on the percutaneous absorption of minoxidil from 5% topical solution. J Invest Dermatol 1990; 94:524 (Abstract).
58. Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL. Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990; 126:756-759.
59. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52:138-139.
60. Bernardo O, Tang L, Lui H, Shaprio J. Topical nitrogen mustard in the treatment of alopecia areata: a bilateral comparison study. J Am Acad Dermatol 2003; 49:291-294.
61. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997; 36:114-117.
62. Ellis CN, Brown MF, Voorhees JJ. Sulfasalazine for alopecia areata. J Am Acad Dermatol 2002; 46:541-544.
63. Sasmaz S, Arican O. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study. Am J Clin Dermatol 2005; 6:403-406.
64. Tosti A, Manuzzi P, Gasponi A. Thymopentin in the treatment of severe alopecia areata. Dermatologica 1988; 177:170-174.
65. Goddard CIR, August PJ, Whorwell PJ. Alopecia totalis in a patient with Crohns disease and its treatment with azathioprine. Postgrad Med 1989; 65:188-189.
66. Namazi MR. The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata. Med Hypotheses 2003; 60:513-514.
67. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4:567-575.
68. McDonald-Hull SP, et al. Immunohistologic and ultrastructural comparison of the dermal papilla and hair follicle bulb from "active" and "normal" areas of alopecia areata. J Invest Dermatol 1991; 96:673-681.
69. Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003; 139:1555-1559.
70. Society for Investigative Dermatology meeting. Poster presentation, 2007.
71. Price VH, Hordinsky, MK, Olsen E, et al. Efficacy and safety results of a clinical study of efalizumab in patients with alopecia areata. J Am Acad Derm (submitted).